bioRxiv Science⌕ Search

Biology subjects

Abdelnaby, M.

Publications and source records attributed to Abdelnaby, M..

2 recordsLinked to original sources

Restoring neurovascular coupling in Alzheimer's disease tauopathy through M1 mAChR modulation

Alzheimer's disease is characterized by progressive cognitive decline and early cerebrovascular dysfunction, including impaired neurovascular coupling (NVC) and reduced cerebral blood flow (CBF). Tau pathology is a major driver of these deficits, yet therapeutic strategies targeting tau-induced neurovascular dysfunction remain limited. The M1 muscarinic acetylcholine receptor (M1 mAChR) is a promising therapeutic target because of its critical role in cognition. We previously demonstrated that pharmacological activation of M1 mAChR improves cognitive function and neuronal survival in amyloid-based Alzheimer's disease mouse models through sex-specific mechanisms. However, whether M1 mAChR activation restores tau-mediated NVC deficits remains unknown. P301S mice were used as a model of tauopathy. Cognitive function was evaluated using the novel object recognition and Morris water maze tests, and NVC was assessed by measuring whisker stimulation-induced changes in CBF using laser speckle contrast imaging. Following baseline measurements, mice received an acute intraperitoneal injection of VU0486846, a selective M1 mAChR positive allosteric modulator (3 mg/kg), and CBF responses were reassessed over time. P301S tau mice exhibited impaired recognition and spatial memory functions, associated with reduced whisker stimulation-induced increase in CBF, indicative of impaired NVC response, while acute treatment with VU0486846 reversed these changes in NVC. This rescuing effect of VU0486846 was observed earlier in female tau mice compared to males, suggesting a sex-biased effect of M1 mAChR modulation. These findings demonstrate that M1 mAChR positive allosteric modulation reverses tau-induced neurovascular dysfunction, supporting M1 mAChR activation as a promising disease-modifying approach for Alzheimer's disease. The earlier improvement observed in females further suggests that therapeutic efficacy is influenced by biological sex.

pharmacology and toxicology↗

A Benchmarking Study of Random Projections and Principal Components for Dimensionality Reduction Strategies in Single Cell Analysis

Principal Component Analysis (PCA) has long been a cornerstone in dimensionality reduction for high-dimensional data, including single-cell RNA sequencing (scRNA-seq). However, PCAs performance typically degrades with increasing data size, can be sensitive to outliers, and assumes linearity. Recently, Random Projection (RP) methods have emerged as promising alternatives, addressing some of these limitations. This study systematically and comprehensively evaluates PCA and RP approaches, including Singular Value Decomposition (SVD) and randomized SVD, alongside Sparse and Gaussian Random Projection algorithms, with a focus on computational efficiency and downstream analysis effectiveness. We benchmark performance using multiple scRNA-seq datasets including labeled and unlabeled publicly available datasets. We apply Hierarchical Clustering and Spherical K-Means clustering algorithms to assess downstream clustering quality. For labeled datasets, clustering accuracy is measured using the Hungarian algorithm and Mutual Information. For unlabeled datasets, the Dunn Index and Gap Statistic capture cluster separation. Across both dataset types, the Within-Cluster Sum of Squares (WCSS) metric is used to assess variability. Additionally, locality preservation is examined, with RP outperforming PCA in several of the evaluated metrics. Our results demonstrate that RP not only surpasses PCA in computational speed but also rivals and, in some cases, exceeds PCA in preserving data variability and clustering quality. By providing a thorough benchmarking of PCA and RP methods, this work offers valuable insights into selecting optimal dimensionality reduction techniques, balancing computational performance, scalability, and the quality of downstream analyses.

bioinformatics↗